(Q53630404)

16 May 2018

title

Gefitinib and the modulation of the signaling pathways downstream of epidermal growth factor receptor in human liver cancer cells. (English)

1 reference

16 May 2018

1 reference

Jun-Ichi Okano

1

1 reference

16 May 2018

Kazuya Matsumoto

series ordinal

2

1 reference

16 May 2018

Takakazu Nagahara

series ordinal

3

1 reference

16 May 2018

Yoshikazu Murawaki

series ordinal

4

1 reference

16 May 2018

publication date

1 February 2006

1 reference

16 May 2018

Journal of Gastroenterology

published in

1 reference

16 May 2018

volume

41

1 reference

16 May 2018

issue

2

1 reference

16 May 2018

page(s)

166-176

1 reference

16 May 2018

Re: Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00535-005-1736-3

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

12 December 2020

Transforming growth factor-alpha and epidermal growth factor receptor in chronic liver disease and hepatocellular carcinoma

1 reference

12 December 2020

Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation.

1 reference

12 December 2020

Role of vitamin K2 in the development of hepatocellular carcinoma in women with viral cirrhosis of the liver

1 reference

12 December 2020

Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: Ethanol injection therapy and radiofrequency ablation

1 reference

12 December 2020

United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets

1 reference

12 December 2020

Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer

1 reference

12 December 2020

Targeting epidermal growth factor receptor in lung cancer

1 reference

12 December 2020

Akt/protein kinase B isoforms are differentially regulated by epidermal growth factor stimulation.

1 reference

12 December 2020

Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor

1 reference

12 December 2020

Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 ('Iressa') induces cell-cycle arrest and inhibits proliferation in prostate cancer cells.

1 reference

12 December 2020

Modulation of survival signaling pathways and persistence of the genotoxic stress as a basis for the synergistic interaction between the atypical retinoid ST1926 and the epidermal growth factor receptor inhibitor ZD1839.

1 reference

12 December 2020

Induction of apoptosis and inhibition of cell growth are independent responses to interferon-alpha in hematopoietic cell lines

1 reference

12 December 2020

Development of liver tumors in transforming growth factor alpha transgenic mice.

1 reference

12 December 2020

ErbB2 overexpression in mammary cells upregulates VEGF through the core promoter

1 reference

12 December 2020

Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis

1 reference

12 December 2020

Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathwa

1 reference

12 December 2020

Synergistic interaction between gefitinib (Iressa, ZD1839) and paclitaxel against human gastric carcinoma cells

1 reference

12 December 2020

Molecular mechanisms of ZD1839-induced G1-cell cycle arrest and apoptosis in human lung adenocarcinoma A549 cells

1 reference

12 December 2020

Expressions of epidermal growth factor family and its receptor in hepatocellular carcinoma cell lines: relationship to cell proliferation.

1 reference

12 December 2020

Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments

1 reference

12 December 2020

Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer

1 reference

12 December 2020

Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level

1 reference

12 December 2020

Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma.

1 reference

12 December 2020

Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck

1 reference

12 December 2020

ZD1839 modulates paclitaxel response in renal cancer by blocking paclitaxel-induced activation of the epidermal growth factor receptor-extracellular signal-regulated kinase pathway

1 reference

12 December 2020

A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients

1 reference

12 December 2020

ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression

1 reference

12 December 2020

Laminin-5 offsets the efficacy of gefitinib ('Iressa') in hepatocellular carcinoma cells.

1 reference

12 December 2020

Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer

1 reference

12 December 2020

Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells

1 reference

12 December 2020

Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis

1 reference

12 December 2020

10.1007/S00535-005-1736-3

Identifiers

DOI

1 reference

16 May 2018

1 reference

16 May 2018